Theriva Biologics, Inc.
TOVX
$0.25
$0.014.52%
AMEX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 300.00K | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 300.00K | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 300.00K | -- | -- | -- | -- |
| SG&A Expenses | 16.21M | 15.59M | 15.39M | 15.85M | 6.42M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 22.20M | 24.19M | 25.75M | 26.39M | 17.96M |
| Operating Income | -21.90M | -24.19M | -25.75M | -26.39M | -17.96M |
| Income Before Tax | -21.46M | -23.74M | -26.19M | -29.56M | -24.81M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -21.46 | -23.74 | -26.19 | -29.56 | -24.81 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -21.46M | -23.74M | -26.19M | -29.56M | -24.81M |
| EBIT | -21.90M | -24.19M | -25.75M | -26.39M | -17.96M |
| EBITDA | -21.80M | -24.09M | -25.64M | -26.28M | -17.83M |
| EPS Basic | -2.55 | -4.06 | -5.53 | -11.89 | -20.68 |
| Normalized Basic EPS | -1.54 | -2.48 | -3.37 | -5.50 | -7.93 |
| EPS Diluted | -2.55 | -4.06 | -5.53 | -11.89 | -20.68 |
| Normalized Diluted EPS | -1.54 | -2.48 | -3.37 | -5.50 | -7.93 |
| Average Basic Shares Outstanding | 86.78M | 48.49M | 22.00M | 13.46M | 7.49M |
| Average Diluted Shares Outstanding | 86.78M | 48.49M | 22.00M | 13.46M | 7.49M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |